© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
April 19, 2021
In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.
The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.
The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.
An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.
The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.
April 18, 2021
The chief of neurology at Ascension Saint Agnes discussed how providing an overview of patient-specific risk factors and mitigation can improve poststroke care.
Aducanumab currently sits before the FDA for review for the treatment of Alzheimer disease, with a PDUFA date set for June 7, 2021.
Results from the ongoing clinical trial will help define clinical management guidelines for switching patients with relapsing MS on other disease-modifying therapies to siponimod.
No stimulation adverse effects were reported, and patients on the MICC stimulation alone resulted in greater than 50% improvement in UPDRS motor scores.
April 17, 2021
Researchers from Ascension Saint Agnes improved compliance in their hospital in providing patient-specific, stroke-dedicated discharge instructions.